Every S-1 that INVO Fertility, Inc. (IVF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow IVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVF filings page.
INVO Fertility, Inc. has registered up to 20,000,000 shares of common stock for resale by Alumni Capital LP under an Any Market Purchase Agreement. INVO may sell shares to Alumni over time for up to $15,000,000 in gross proceeds, potentially $50,000,000 by mutual agreement, but receives no cash from Alumni’s resales. Common shares outstanding were 2,295,035 as of July 23, 2026, so full use of the facility would be highly dilutive. Issuances are limited by a 9.99% Beneficial Ownership Limitation and Nasdaq’s 19.99% Exchange Cap, for which stockholders have approved exceeding.
INVO is a healthcare services and technology company focused on fertility, operating four U.S. clinics and commercializing its INVOcell intravaginal culture device. Recent actions include acquiring Family Beginnings in Indiana for approximately $760,000 and buying the remaining membership interests in its Alabama joint venture for $175,001, bringing that clinic fully into consolidated results.
Stockholders approved increasing authorized common shares to 250,000,000, and a 1‑for‑5 reverse split took effect in March 2026. A May 2026 amendment extended $660,000 of JAG convertible notes, now reduced to $287,333, and added resettable conversion and warrant terms. Independent auditors’ reports for 2024 and 2025 include going‑concern explanatory paragraphs, and company disclosures emphasize risks from substantial dilution and variable‑price equity financing.
INVO Fertility, Inc. is registering up to 9,467,456 shares of common stock for resale by Armistice Capital Master Fund Ltd. These shares are issuable upon exercise of an Inducement Warrant with a $1.59 per share exercise price. INVO is not selling any shares in this offering, but could receive up to $15,053,255 in gross proceeds if the warrant is fully exercised for cash.
Shares of common stock outstanding were 6,961,095 as of January 30, 2026, and are expected to be 16,428,551 after this offering. INVO plans to use any warrant exercise proceeds primarily for acquiring additional fertility clinics and related businesses, capital expenditures, working capital, and general and administrative expenses. The company warns that issuance and resale of these shares could dilute existing stockholders and put pressure on the IVF share price.
INVO Fertility, Inc. has filed a resale registration statement covering up to 7,372,122 shares of common stock for existing investors. These shares include 153,187 shares issuable upon conversion of Series C-2 preferred stock, 118,343 shares issuable under a placement agent warrant, and 7,100,592 shares tied to a recent $4 million private placement with Armistice Capital, made up of issued shares and shares underlying pre-funded and common warrants.
The company is not selling shares itself in this offering and will not receive proceeds from Selling Stockholders’ resales, though it may receive cash if the registered warrants are exercised. As context, common shares outstanding were 2,386,826 as of December 16, 2025, and could rise to 9,523,948 if all registered convertible and warrant securities are fully exercised or converted. INVO focuses on fertility clinics and its INVOcell intravaginal culture device and has agreed to acquire the Family Beginnings fertility clinic in Indianapolis for $750,000 in cash and new Series D preferred stock, subject to closing conditions.
INVO Fertility, Inc. filed an S-1 to register up to 8,345,774 shares of common stock for resale by Five Narrow Lane LP. The Shares comprise up to 770,973 shares issuable upon exercise of an Inducement Warrant and up to 7,574,801 shares issuable upon conversion of Series C-2 Non-Voting Convertible Preferred Stock.
The company is not selling any shares and will not receive proceeds from reseller transactions; it may receive up to $344,000 only if the Inducement Warrant is exercised. A 9.99% beneficial ownership cap applies to conversions and exercises. INVO will bear registration expenses, while the selling stockholder will bear selling costs.
Common stock trades on Nasdaq as “IVF”; the last reported price was $0.7283 per share on October 13, 2025. Shares outstanding were 5,624,012 as of October 13, 2025. The filing permits multiple sale methods, including exchange and over-the-counter transactions, privately negotiated sales, and short sales after effectiveness.